Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 28, 2012; 18(16): 1884-1891
Published online Apr 28, 2012. doi: 10.3748/wjg.v18.i16.1884
Published online Apr 28, 2012. doi: 10.3748/wjg.v18.i16.1884
Figure 4 Effects of antithrombin III on hepatic mRNA expression of lactate dehydrogenase and heme oxygenase-1.
Hepatic mRNA expression of lactate dehydrogenase (LDH) (A) and heme oxygenase (HO)-1 (B) was determined by real-time polymerase chain reaction. Reactions were normalized for glyceraldehyde-3-phosphate dehydrogenase expression and the relative expression in the untreated liver was used as a control. Control: Untreated; TV: Antithrombin (AT) III injection via the tail vein; PV: AT III injection via the portal vein. Values are means ± SD (n = 10 rats/group). aP < 0.05 vs the tail vein group and the control group.
-
Citation: Miyazaki M, Kato M, Tanaka M, Tanaka K, Takao S, Kohjima M, Ito T, Enjoji M, Nakamuta M, Kotoh K, Takayanagi R. Antithrombin III injection
via the portal vein suppresses liver damage. World J Gastroenterol 2012; 18(16): 1884-1891 - URL: https://www.wjgnet.com/1007-9327/full/v18/i16/1884.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i16.1884